Program of the day *

WIN-WIN COLLABORATION: HOW CAN BIG PHARMA COMPANIES AND FRENCH START-UPS GET IT DONE?

(*subject to modification)

Jeffrey Almond, PhD, Vice President, Discovery Research and External R&D, Sanofi Pasteur*
Title: R&D Collaborations, which issues?

Marjorie Sidhoum, CEO, Almetis
Title: Ruthenium complexes: a new class of anticancer molecules with specific mechanism of action
Jonathan Stauber, CEO, Imabiotech
Title: ISAMS : When innovations accelerate multiplex diagnostic assay
JOHN POULOS, GROUP VICE PRESIDENT PHARMACEUTICAL LICENSING & ACQUISITIONS, ABBOTT
Mohammad Afshar, CEO, Ariana Pharma
Title: Improving clinical trial outcome, Rescuing failed trials, Multiplexing biomarkers: towards improved design through exhaustive multiparametric data analysis
Olivier Kitten, CEO, Affilogic
Title: Nanofitins: an alternative to antibodies for capture, detection and targeting
CHRISTINE GRYGON, Ph.D, HEAD, BI PARTNERING - BUSINESS DEVELOPMENT AND LICENSING, BOEHRINGER-INGELHEIM

Christophe Lautrette, CEO, Oncomedics
Title: Optimal drug selection using cultures from human tumor samples

Nathalie Compagnone, CEO, ICDD
Title: New strategies in Pharmaceutical Companies, new business model for ICDD

MANFRED HORST, DIRECTOR LICENSING EUROPE, MERCK & CO

Thierry Abribat, CEO, Alizé Pharma
Title: Early partnerships as business strategy for drug development biotech companies : the example of Alizé Pharma

Intermediate closing note Title: Investments for the Future: overview of the different French programs

Bruno Pitard, Ph.D. Founder, Research and Development, In Cell Art
Title: Collaborative programs for the discovery of innovative vaccines and antibodies
Vianney Souplet, CEO, Innobiochips
Title: Partnering for innovating multiplex lab on a chips protein assays
GUY R SEABROOK, PhD., SENIOR DIRECTOR, GLOBAL EXTERNAL R&D - LILLY RESEARCH LABORATORIES, ELI LILLY & COMPANY
Grégoire Franoux, Director New Business Development, Flamel
Title: Innovative formulation approaches for the development of Biobetter drugs
Jean-Baptiste Dumas Milne Edwards, CEO, Helios Biosciences
Title: Large scale dynamic models of cell signalling networks to accurately select therapeutic targets and biomarkers
JOHN GUSTOFSON, DIRECTOR OF STRATEGIC PARTNERING AND BUSINESS DEVELOPMENT, ASTRAZENECA

Philippe Mondon, Head of Research, Millegen
Title: Therapeutic antibody development using MilleGen's fully human antibody platform
Fabien Granier, Manager, Colcom
Title: Nanomolecules for Magnetic Resonance Imaging or Gene Delivery
PRAKASH PUROHIT, ASSOCIATE DIRECTOR, SCIENTIFIC AFFAIRS, IPSEN US
Pascal Neuville, CEO, Domain Therapeutics
Title: ARAMIS : From a collaborative project to a Pharma-Biotech deal

Elias ZERHOUNI, President, Global R&D Worldwide, Sanofi Title: Expectations from pharma to address translational medicine challenges ?

*to be confirmed